New drug MIB-725 gets first safety check in healthy volunteers
NCT ID NCT06815991
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called MIB-725 in 32 healthy adults aged 19 to 60. Participants receive a single dose (100 to 800 mg) and are monitored for side effects and how the drug moves through the body. The goal is to see if the drug is safe before testing it in people with a disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2025
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Is a non-smoking healthy adult, 19 to 60 years of age, inclusive 2. Has a body mass index (BMI) between 19 and 37.5 kg/m2, inclusive 3. Is free from clinically significant medical problems as determined by the Investigator 4. Is able and willing to provide written informed consent. 5. Is able and willing to provide authorization for the use and disclosure of personal health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA). Exclusion Criteria: 1. Is a current cigarette smoker 2. AST or ALT \> 1.5 times the upper limit of normal 3. Hematocrit \< 37% or \> 51% 4. Diagnosis of diabetes mellitus, as indicated by use of diabetes medication, hemoglobin A1C \> 6.4% or fasting glucose ≥126 mg/dL 5. Serum creatinine \> 2.0 mg/dL 6. Current use of barbiturates, benzodiazepines, opiates, amphetamine, cannabinoids and cocaine 7. Known allergy to niacin or nicotinamide mononucleotide 8. Unwilling to refrain from drinking alcohol during the duration of the study 9. Use of any other dietary supplement during the course of the trial 10. Use of anabolic steroids, rhGH, DHEA, androstenedione, or any other performance enhancing drug 11. In the judgment of the study physician, the participant is unlikely to comply with the study protocol for any reason or it may not be safe to administer the study medication 12. Has a history of myocardial infarction, stroke, or heart failure in the preceding 6 months. 13. Has a history of cancer other than nonmelanotic skin cancer requiring treatment in the previous 2 years. 14. Has other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results. In addition, female participants must: 1. Be postmenopausal as indicated by cessation of menstruation at least one year before screening 2. Not be pregnant and not planning to become pregnant over the next 6 months Prohibited medications and substances: 1. Current use of barbiturates, benzodiazepines, opiates, amphetamine, cannabinoids and cocaine 2. Use of any other dietary supplement during the course of the trial. Subjects who are using a supplement containing nicotinamide, niacin, nicotinamide mononucleotide, or nicotinamide riboside may be included if they agree to stop the supplement at least 2 weeks prior to day 0 and during the entire duration of the study. 3. Initiation of a new prescription drug during the preceding 4 weeks or during the course of the study 4. Use of anabolic steroids, rhGH, DHEA, androstenedione, or any other performance enhancing drug \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy adults are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Carbs or protein before exercise: does sex change how your body burns fuel?
- Two brain scanners, one stimulation session: can they agree?
- First human test of experimental pill XH-S004 begins in healthy volunteers
- Can video games keep your brain sharp? trial pits xbox against Paper-and-Pencil training
- Ultrasound pulses aimed at deep brain regions tied to empathy and impulse control
- A dead Probiotic's ghost may help tame weight gain